|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 11, 2012 ) Boca Raton, FL --- Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics. Its lead drug, voclosporin, is an immunosuppressant designed to effectively prevent organ transplant rejection, while providing significant safety advantages over currently available treatments.
The Company has successfully completed Phase 2 clinical trials for voclosporin, and plans to initiate a phase 3 clinical trial program in 2012 for the prevention of kidney transplant rejection. The phase 3 trials will take place in the United States, Canada and in Europe.
“We are committed to developing new medicines to improve the lives of organ transplant patients around the world. Our lead product, voclosporin, will be entering the final phase of clinical testing for the prevention of kidney transplant rejection. We are excited and optimistic about the prospects for voclosporin and for our company. We look forward to generating significant value for investors, and better health outcomes for the transplant patients that will benefit from our drug,” commented Dr. Robert Foster, CEO of Isotechnika.
About Isotechnika Pharma Inc.
Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are designed to offer key safety advantages over currently available treatments. Its lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at the estimated US$3.0 billion market for this class of immunosuppressants.
Isotechnika Pharma Inc. trades on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at www.isotechnika.com or www.sedar.com.
About 21st Century Health
21st Century Health is an award winning targeted business show that is independently produced by Multi-Media Productions. The show provides its business viewers an in depth opportunity to find solutions to the industry problems from some of the top business leaders from across the world. Each exclusive segment is taped in our state of the art South Florida Studio.
Once selected, companies are able to present their story and solutions to industry problems in an exclusive way that sets their company apart from the others. With more than 6,000 companies participating on over 600 shows, 21st Century Health continues to be the premier and targeted outlet for the latest business stories.
Isotechnika will be featured on CNBC (as paid programming) and Fox Business Network (as paid programming.) In addition, their segment will be featured on Health and Science Television, the Long Term Care Network. Isotechnika’s segment will also be shown on Campus TV/Curricula at leading universities such as Dartmouth, Princeton, Georgetown, Carnegie Mellon, New York University and many more.
21st Century Health airs on various national cable networks that are viewed by over 100 million viewers nationwide as well as internationally via DirecTV and Dish Network. The show can also be viewed through video on demand via http://www.21chtv.com.
For specific market-by-market air dates and times, please e-mail Moniqueh@mmpusa.com. For more information, please visit http://www.21chtv.com.
Multi-Media Productions USA
Susan Waters
919 732 3070
swaters@mmpusa.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
